$200 million in Series C investment was secured by Zenas BioPharma, a biopharmaceutical firm located in Waltham, Massachusetts that develops treatments focused on inflammation and immunology.
Investors
- Fairmount
- Wellington Management
- Rock Springs Capital
- Pivotal bioVenture Partners
- Vivo Capital
- Quan Venture Fund
- Superstring Capital
- SR One
- NEA
- Norwest Venture Partners,
- Delos Capital
Other participants included Enavate Sciences, Longitude Capital, the Federated Hermes Kaufmann Funds, and Arrowmark Partners. Tim Xiao, a partner at Delos Capital, and Jake Nunn, a venture partner at SR One, joined Zenas’ board of directors in tandem with the funding.
Use of funds
With obexelimab, a bifunctional monoclonal antibody that binds both CD19 and FcγRIIb to inhibit the activity of B cells, plasmablasts, and CD19-expressing plasma cells, the company plans to use the funds to advance ongoing mid- to late-stage clinical development programs for its lead product candidate.
About Zenas BioPharma
Zenas BioPharma, a clinical-stage biopharmaceutical business led by CEO Lonnie Moulder, is dedicated to creating and distributing inflammation and immunology (I&I) tailored treatments for patients in need globally. It is pursuing a portfolio of potentially distinct autoimmune therapies in areas of high unmet medical need using its worldwide operations and clinical development expertise.
“We are pleased and appreciative of the support we have received from this group of tremendous life sciences investors as we advance the ongoing obexelimab development program across multiple auto-immune diseases.”
Lonnie Moulder
The clinical initiatives for obexelimab comprise an ongoing open label Phase 2 trial in Warm Autoimmune Hemolytic Anemia, two planned Phase 2 randomized controlled trials in Multiple Sclerosis and Systemic Lupus Erythematosus, and a Phase 3 registration-directed trial in IgG4-Related Disease.
